1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |

---

According to the reports of Phase III trial of Blinatumomab, Blinatumomab significantly extended event free survival compared with conventional consolidation chemotherapy among children with high-risk B-cell acute lymphoblastic leuk...

Read More

---

Coxsackievirus - A Common Cold Virus Can Treat Bladder Cancer

Release Date: 03 October 2019

According to the Findings of a study published in Clinical Cancer Research, oncolytic virus coxsackievirus showed prominent action in a small cohort study of patients with non-muscle-invasive bladder cancer. This approach of usi...

Read More

---

TG4001 and Avelumab Combo Shows High Efficacy against HPV-Positive Cancer

Release Date: 03 October 2019

On 30 September 2019, a safety and efficacy data of TG4001 in combination with avelumab (BAVENCIOandreg;) is presented by Transgene, a biotech company. Transgene is known to designs and develops virus-based immunotherapeutics against can...

Read More

---

Combo of Precision Vaccine and Maintenance Therapy Shows Prominent Action in Phase 1/2 Trial against Colorectal Cancer

Release Date: 03 October 2019

According to the findings of Phase 1/2 Clinical Trial conducted by Treos Bio Limited, the combination of personal cancer vaccine with cancer maintenance therapy shows positive results in patients with microsatellite-stable (MSS) metastat...

Read More

---

World’s First Chlamydia Vaccine Got Success in Phase I Trial

Release Date: 01 October 2019

According to the recently published study in Lancet Infectious Disease Journal, the world’s first chlamydia vaccine has been found to be safe and efficacious in the Phase I study and it is able to stimulate an immune response. The ...

Read More

---

CRISPR Can Enhance the Hybridoma Technology

Release Date: 01 October 2019

According to the study published in journal Science Advance, a team of researchers incorporates CRISPR/HDR along with the Hybridoma technology to boost the process of antibodies production. This could have huge implications for futu...

Read More

---

Roche’s Tecentriq Shows Prominent Action against Advanced Bladder Cancer in Phase III Trial

Release Date: 01 October 2019

On 30 September 2019, Roche’s Tecentriq (Atezolizumab) presented positive results in the Phase III IMvigor130 study. The study involves a combinational therapy along with platinum-based chemotherapy versus chemotherapy alone for th...

Read More

---

Antibiotics can Reduce Checkpoint Inhibitor’s Activity

Release Date: 01 October 2019

According to the findings of a new study published in JAMA Oncology, the efficacy and patient’s response towards the Immune Checkpoint inhibitors decreases when an antibiotic treatment is given within the 30 days of initiation of t...

Read More

---

APVO603 - A New Adaptir™ Bispecific Antibody against Solid Tumors

Release Date: 01 October 2019

On 19 September 2019, Dr. Jane Gross, Chief Scientific Officer for Aptevo, presented a preclinical data on APVO603, which is a new candidate of Adaptir platform, in an oral presentation at the 10th Annual World Bispecific Summit in Walth...

Read More

---

New Combo to Boost KAS Inhibitors Activity Against Lung Cancer

Release Date: 01 October 2019

Recently, a team of researchers found that the by suppressing  two more tumor-related proteins along with the use of KRAS inhibitors shows positive effects in the treatment of lung cancer. The early evidence of the study shows that ...

Read More

---

A New Single Therapy Shows Positive Activity against Various Cancer Forms

Release Date: 30 September 2019

The research Team from the University of California Los Angeles has developed a new innovative treatment method that enhances the levels of specific type of immune cell and improves the immune response so that it becomes capable of fight...

Read More

---

PARP Drugs Can Control metastatic castration-resistant prostate cancer

Release Date: 30 September 2019

The recent research led by Maha Hussain, MD, of Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago confirmed that the data from the phase 3 PROfound trial shows olaparib action in slowing the cancer progres...

Read More

---

New Frontline Combinational Therapy For Ovarian Cancer

Release Date: 30 September 2019

According to the findings of a recent study of phase III PAOLA-1 trial presented at the European Society for Medical Oncology (ESMO) Congress 2019, a new combinational therapy consisting olaparib (Lynparza) and bevacizumab (Avastin)...

Read More

---

A New Monoclonal Antibody Can Suppress Nipah Virus Infection

Release Date: 30 September 2019

Recently, a new monoclonal antibody has been developed by the researchers, which is able to inhibit the fusion machinery henipaviruses, which results in the merging of virus with the cells. The antibody restricts the attack by blocking m...

Read More

---

Afatinib A Potent Option for NRG1+ cancer Treatment

Release Date: 30 September 2019

A recent study confirmed that Afatinib (Gilotrif) has a potential for the treatment of patients with NRG1-positive tumors across multiple cancer types. The study is presented at the ESMO 2019 Congress and it is presented by...

Read More

---

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 |